[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2025-03-09
飞白2021
来自湖南省
审稿速度:2.0 | 投稿命中率:75.0偏重的研究方向:乙肝;病毒学;肝癌经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!
37
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2023-09-17
evolsy
来自四川省
审稿速度:2.0经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分
151
3
举报
展开3条回复
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2024-09-29
ms3000001305381970
来自云南省
病毒性腹泻方面的文章好投么?
50
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2024-03-30
songgao
来自云南省
审稿速度:2.0 | 投稿命中率:25.0偏重的研究方向:新冠经验分享:投了一篇,大修返回去了,希望好运
144
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2024-03-14
ms9000001232984305
来自广东省
Initial SubmissionThis submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?
121
1
举报
展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2024-02-29
loe1
来自湖北省
审稿速度:3.0 | 投稿命中率:50.0偏重的研究方向:化药经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。
164
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2024-01-02
ms5000000098138879
来自广东省
审稿速度:2.0 | 投稿命中率:75.0偏重的研究方向:试验;新冠;临床经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯
134
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2023-12-28
ms8000000268543706
审稿速度:3.0 | 投稿命中率:75.0偏重的研究方向:新冠;临床经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online
133
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2023-12-27
ms8000001944553936
来自广东省
偏重的研究方向:疫苗;新冠;病毒学经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊
163
0
举报
[GetPortalCommentsPageByObjectIdResponse(id=2255296, encodeId=f892225529601, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:乙肝;病毒学;肝癌
经验分享:研究方向是HBV相关肝癌的发生机制。2024年10月15投稿,然后就一直是under review,过了一个月,发邮件闻了一下,说还是做决定;11月27日收到修稿信,给了大修,还算比较快,大修给了两个月,团队抓紧补实验,在过年前2025年1月23日修回去了,可能赶上过年了,审稿又比较慢,直到2025年2月25日,非常突然的接收了,没有小修,说是两个审稿人都很满意,每一条都认真补实验回应了,非常感谢大家的分享,我也来分享下供大家参考,这个杂志整体速度还是中等,接收后10天proof,目前已经提交proof了,等待online,proof前要填写相关信息,可以选择OA或者订阅模式,OA4730美元,太贵,我选了订阅模式,方便!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7b362807070, createdName=飞白2021, createdTime=Sun Mar 09 09:17:47 CST 2025, time=2025-03-09, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0
经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2228385, encodeId=2d52222838544, content=病毒性腹泻方面的文章好投么?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37e18406011, createdName=ms3000001305381970, createdTime=Sun Sep 29 16:21:29 CST 2024, time=2024-09-29, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2196201, encodeId=c5d2219620113, content=审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向:新冠
经验分享:投了一篇,大修返回去了,希望好运, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/uSLBKdqq7TRFaLXdGd2VZ7Z93BKRY9uuvO1VCO2D8JOibXs0lRHhPsIP8dAHnnEicll9KS9ib6mPXXBvk9qYovtcg/132, createdBy=717d5291157, createdName=songgao, createdTime=Sat Mar 30 10:34:06 CST 2024, time=2024-03-30, status=1, ipAttribution=云南省), GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission
This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向:化药
经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向:试验;新冠;临床
经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向:新冠;临床
经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学
经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省)]
2023-09-19
南大
来自江苏省
请问这个杂志一审多久?
27
0
举报